Eli Lilly and Incyte's eczema treatment delayed at FDA – again

The two pharmaceutical companies have been forced to announce that the FDA's processing of Olumiant as a treatment for atopic dermatitis has been delayed for a second time. This is due to questions surrounding the drug class.

Photo: Mike Blake/REUTERS / X00030

The US Food and Drug Administration, FDA, has again postponed its deadline for responding to Eli Lilly's application for the authorization of Olumiant, which is an eczema treatment for adults.

Eli Lilly and Incyte, the two firms collaborating over the drug, have therefore announced that the FDA will not respond in line with its original deadline, which was the third quarter of this year. They have not revealed when they now expect a response.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs